AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy

Given that analysts also expect Ginkgo's top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this point. Meanwhile, on April 10, Ginkgo and Novo Nordisk (NYSE:NVO) disclosed they had expanded their strategic partnership. Under the five-year deal, the firms will seek "to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medicatio ...